Brevibloc Esmolol Hydrochloride Injection 100mg/10mL - Intravenous (IV) Use

Brevibloc Esmolol Hydrochloride Injection 100mg/10mL - Intravenous (IV) Use

Brevibloc Esmolol Hydrochloride Injection is a cardioselective beta-1 receptor blocker, specifically formulated for intravenous administration. It is designed to provide rapid onset and short duration of action for the management of acute cardiac conditions where control over heart rate and myocardial contractility is essential.

Product Specifications:
- Concentration: 100mg Esmolol Hydrochloride per 10mL
- Presentation: Clear, colorless, sterile solution
- Packaging: Single-use vials to ensure safety and sterility
- Storage: Store between 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)
- Compatibility: Should not be mixed with alkaline solutions

Common Applications:
- Supraventricular tachycardia: Rapidly reduces heart rate
- Noncompensatory sinus tachycardia: Provides rate control where vagal maneuvers and other measures fail
- Perioperative tachycardia and hypertension: Used during surgery to manage tachycardia and hypertension that occur intraoperatively
- Acute myocardial infarction: Slows heart rate and decreases myocardial oxygen demand

User Groups:
- Cardiologists and cardiac surgeons
- Anesthesiologists
- Emergency medicine physicians
- Critical care and intensive care unit medical staff

Supplier Overview:
Phebra is an established pharmaceutical company specializing in the development and manufacturing of injectable pharmaceuticals. With a strong commitment to quality and patient safety, Phebra has positioned itself as a trusted authority in the critical care and emergency medicine sectors. Their rigorous quality control measures and dedication to therapeutic innovation make them a reliable source for Brevibloc Esmolol Hydrochloride Injection, ensuring that healthcare professionals have access to effective and safe medications for managing acute cardiac conditions.